# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce retina and retinal pigment epithelium
- describe retinal pigment epithelium function
- discuss retinal diseases and disorders
- highlight need for new treatments

## BRIEF SUMMARY OF THE INVENTION

- introduce method of treating retinal disease
- specify compounds and targets
- list retinal diseases and disorders
- describe compound administration
- specify pharmaceutical composition
- introduce method of treating retinal degeneration
- specify compounds and targets
- describe compound administration
- introduce method of restoring retinal pigment epithelium cells
- specify compounds and targets
- describe compound administration

## DETAILED DESCRIPTION OF THE INVENTION

- define terms and conventions
- describe scope of disclosure
- explain interpretation of ranges and values
- define articles and conjunctions
- explain "and/or" and "or" phrases
- describe transitional phrases in claims
- explain "at least one" phrase
- describe method step ordering
- define co-administration and combination therapy
- define compound and related terms
- introduce therapeutic compounds and their functions
- introduce NF-κB protein complex
- describe role of NF-κB in cellular responses
- introduce mTOR protein kinase
- describe role of mTOR in cellular processes
- introduce Rho GTPases
- describe role of Rho GTPases in signal transduction pathways
- introduce serine proteases
- describe role of serine proteases in disease states
- introduce dopamine receptors
- describe role of dopamine receptors in CNS
- introduce AMPK enzyme
- describe role of AMPK in cellular energy homeostasis
- describe embodiments of compounds of the invention
- describe pharmaceutical compositions of the invention
- describe administration routes of the invention
- describe pharmaceutical compositions
- formulate injectable forms
- formulate oral dosage forms
- formulate suppositories
- formulate topical forms
- formulate ointments and creams
- formulate ophthalmic forms
- formulate nasal aerosol and inhalation forms
- determine dosage and treatment regimens
- administer compounds
- describe oral compositions
- describe tablets, pills, and capsules
- describe elixirs, suspensions, and syrups
- mix with other active materials
- describe parenteral preparations
- describe controlled release formulations
- describe liposomal suspensions
- provide therapeutic methods
- treat ophthalmic diseases
- treat retinal degradation
- restore retinal pigment epithelium cells
- treat macular degeneration
- provide kits

## EXAMPLES

### Example 1—Complement Competent Human Serum (CC-HS) Induces AMD-Like Cellular Endophenotypes in Mature iPSC-RPE

- introduce iPSC-RPE model
- characterize CC-HS treatment effects on RPE cells
- analyze APOE and lipid deposits
- confirm dedifferentiation of RPE cells

### Example 2—CC-HS Triggered AMD Disease Phenotypes are Induced Through C3aR1 and C5aR1 Signaling

- investigate C3aR1 and C5aR1 receptors in iRPE cells
- analyze CC-HS treatment effects on C3aR1 and C5aR1 signaling

### Example 3—C3aR1 and C5aR1 Induced subRPE Deposits are Mediated by Overactivation of NF-KB and Downregulation of Autophagy Pathways

- analyze RNAseq data for CC-HS treatment effects
- investigate NF-KB pathway activation
- analyze autophagy pathway defects
- confirm NF-KB target gene expression
- analyze cytokine secretion
- investigate NEMO mutation effects on NF-KB signaling

### Example 4—High Throughput Screen to Discover iRPE Cytoprotective Drugs

- design drug screen using A23187
- perform high-throughput screen
- analyze drug screen results

### Example 5—L456,780 and Aminocaproic Acid Reversed CC-HS Induced NF-kB Activation and Autophagy Suppression in iRPE Cells

- analyze effects of L456,780 and aminocaproic acid on NF-KB and autophagy pathways

### Example 6—Restoration of iRPE Epithelial Phenotype In Vitro in CC-HS Treated Cells and In Vivo in a Rat Model

- demonstrate restoration of epithelial phenotype in vitro
- demonstrate restoration of epithelial phenotype in vivo
- confirm restoration of RPE functionality

### Example 7—Mechanism of L-ORD and AMD and Use of Metformin as an Effective Therapy

- introduce L-ORD and AMD
- describe patient-specific iPSCs production
- verify disease mechanism in vitro
- identify relationship between CTRP5 mutation and disease-causing phenotypes
- analyze AMPK activity in L-ORD patient RPE
- investigate CTRP5 as an autocrine regulator of RPE metabolism
- determine CTRP5 expression in L-ORD patients
- identify CTRP5 receptor interaction
- model CTRP5-ADIPOR1 interaction
- simulate S163R mutation in L-ORD
- analyze AMPK signaling in L-ORD patient RPE
- evaluate CTRP5 role in AMPK signaling
- investigate AMPK activity under serum deprivation
- analyze ceramide levels in L-ORD patient RPE
- investigate PEDF-R expression in L-ORD patient RPE
- model PEDF-R mediated retinal neuroprotection
- analyze phagocytic capacity of L-ORD patient RPE
- evaluate phospholipase A2 activity in L-ORD patient RPE
- investigate metformin's effect on AMPK resensitization
- analyze metformin's effect on RPE dedifferentiation
- perform retrospective cohort study of AMD patients treated with metformin

### Example 8—Analysis of iPSC-RPE from Patients with Late-Onset Retinal Degeneration Identifies the Role of AMPK in Regulating Healthy RPE Phenotype and LED to a Re-Purposing of Metformin, a Known Type 2 Diabetes Drug for a Potential Treatment of AMD and Other Retinal Degenerative Diseases

- describe L-ORD pathology
- analyze AMPK signaling in L-ORD patients
- demonstrate metformin treatment effects on L-ORD patients
- illustrate fatty acid oxidation and ketone body formation

### Example 9—Metformin Delays Median-Age of Onset for Retinal Degenerative Diseases

- introduce metformin
- establish safety profile of metformin
- describe retrospective cohort study
- present results of study on metformin's effect on AMD diagnosis
- depict testing data on iPSC-RPE cells
- show expression and localization of CTRP5 in L-ORD patient-derived RPE
- demonstrate reduced antagonism of CTRP5 on ADIPOR1
- show altered AMPK signaling in L-ORD
- depict altered lipid metabolism in L-ORD patients
- demonstrate reduced neuroprotective signaling
- show increased susceptibility to epithelial-mesenchymal transition
- depict effects of metformin treatment on L-ORD patient RPE
- show restoration of PEDF ratio and apical secretion of DHA-derived neuroprotection D1
- demonstrate metformin's effect on delaying age of onset of AMD
- summarize results of retrospective clinical study
- introduce Example 10
- introduce novel therapeutics to improve and maintain RPE healthy phenotype
- introduce Example 9
- downregulate NOX4 using shRNA
- confirm downregulation of NOX4
- perform pharmacological inhibition of NOX4
- introduce Example 11
- describe Stargardt disease
- develop Stargardt iPSC-derived RPE
- validate Stargardt iPSC-derived RPE
- investigate role of ABCA4 in RPE
- test hypothesis of cell autonomous defects
- modulate ABCA1 expression
- determine effect of ABCA1 KD on lipid deposits
- rescue lipid accumulation defects
- propose metformin as therapeutic intervention
- test metformin treatment in Stargardt iRPE
- confirm metformin treatment in Abca4−/− mouse model

## EQUIVALENTS

- define equivalents

